Mitigation Strategies for Pandemic Influenza A: Balancing Conflicting Policy Objectives

Mitigation of a severe influenza pandemic can be achieved using a range of interventions to reduce transmission. Interventions can reduce the impact of an outbreak and buy time until vaccines are developed, but they may have high social and economic costs. The non-linear effect on the epidemic dynamics means that suitable strategies crucially depend on the precise aim of the intervention. National pandemic influenza plans rarely contain clear statements of policy objectives or prioritization of potentially conflicting aims, such as minimizing mortality (depending on the severity of a pandemic) or peak prevalence or limiting the socio-economic burden of contact-reducing interventions. We use epidemiological models of influenza A to investigate how contact-reducing interventions and availability of antiviral drugs or pre-pandemic vaccines contribute to achieving particular policy objectives. Our analyses show that the ideal strategy depends on the aim of an intervention and that the achievement of one policy objective may preclude success with others, e.g., constraining peak demand for public health resources may lengthen the duration of the epidemic and hence its economic and social impact. Constraining total case numbers can be achieved by a range of strategies, whereas strategies which additionally constrain peak demand for services require a more sophisticated intervention. If, for example, there are multiple objectives which must be achieved prior to the availability of a pandemic vaccine (i.e., a time-limited intervention), our analysis shows that interventions should be implemented several weeks into the epidemic, not at the very start. This observation is shown to be robust across a range of constraints and for uncertainty in estimates of both R0 and the timing of vaccine availability. These analyses highlight the need for more precise statements of policy objectives and their assumed consequences when planning and implementing strategies to mitigate the impact of an influenza pandemic.

[1]  Simon Cauchemez,et al.  Assessing the severity of the novel influenza A/H1N1 pandemic , 2009, BMJ : British Medical Journal.

[2]  Kosa Sudhorm,et al.  Pandemic (H1N1) 2009 , 2009 .

[3]  J. Wallinga,et al.  Different Epidemic Curves for Severe Acute Respiratory Syndrome Reveal Similar Impacts of Control Measures , 2004, American journal of epidemiology.

[4]  Neil M. Ferguson,et al.  The effect of public health measures on the 1918 influenza pandemic in U.S. cities , 2007, Proceedings of the National Academy of Sciences.

[5]  Joanna Ellis,et al.  The Early Transmission Dynamics of H1N1pdm Influenza in the United Kingdom. , 2009, PLoS currents.

[6]  M. Lipsitch,et al.  Public health interventions and epidemic intensity during the 1918 influenza pandemic , 2007, Proceedings of the National Academy of Sciences.

[7]  Sally M. Blower,et al.  Imperfect vaccines and herd immunity to HIV , 1993, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[8]  M. Pagano,et al.  Estimation of the reproductive number and the serial interval in early phase of the 2009 influenza A/H1N1 pandemic in the USA , 2009, Influenza and other respiratory viruses.

[9]  Simon Cauchemez,et al.  The Early Transmission Dynamics of H1N1pdm Influenza in the United Kingdom , 2010, PLoS currents.

[10]  M Elizabeth Halloran,et al.  Strategy for distribution of influenza vaccine to high-risk groups and children. , 2005, American journal of epidemiology.

[11]  S. Riley Large-Scale Spatial-Transmission Models of Infectious Disease , 2007, Science.

[12]  N. Arinaminpathy,et al.  Antiviral treatment for the control of pandemic influenza: some logistical constraints , 2008, Journal of The Royal Society Interface.

[13]  David J. Philp,et al.  Quantifying social distancing arising from pandemic influenza , 2007, Journal of The Royal Society Interface.

[14]  Sandra Mounier-Jack,et al.  How prepared is Europe for pandemic influenza? Analysis of national plans , 2006, The Lancet.

[15]  M. Safan,et al.  Title Pros and cons of estimating the reproduction number from earlyepidemic growth rate of influenza A ( H 1 N 1 ) 2009 , 2010 .

[16]  E. Lyons,et al.  Pandemic Potential of a Strain of Influenza A (H1N1): Early Findings , 2009, Science.

[17]  A. Nizam,et al.  Containing pandemic influenza with antiviral agents. , 2004, American journal of epidemiology.

[18]  B. Levin,et al.  Antiviral Resistance and the Control of Pandemic Influenza , 2007, PLoS medicine.

[19]  Stefano Merler,et al.  Age-prioritized use of antivirals during an influenza pandemic , 2009, BMC infectious diseases.

[20]  T. Jefferson,et al.  Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review , 2007, BMJ : British Medical Journal.

[21]  Lisa Sattenspiel,et al.  Simulating the effect of quarantine on the spread of the 1918–19 flu in Central Canada , 2003, Bulletin of mathematical biology.

[22]  D. Cummings,et al.  Strategies for mitigating an influenza pandemic , 2006, Nature.

[23]  Hiroshi Nishiura,et al.  Early Epidemiological Assessment of the Virulence of Emerging Infectious Diseases: A Case Study of an Influenza Pandemic , 2009, PloS one.

[24]  M. van Boven,et al.  Optimizing infectious disease interventions during an emerging epidemic , 2009, Proceedings of the National Academy of Sciences.

[25]  M. Postma,et al.  Investment decisions in influenza pandemic contingency planning: cost-effectiveness of stockpiling antiviral drugs , 2009, European journal of public health.

[26]  C. Fraser,et al.  Factors that make an infectious disease outbreak controllable. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Jit,et al.  Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation. , 2010, Vaccine.

[28]  J Wallinga,et al.  Distribution of vaccine/antivirals and the ‘least spread line’ in a stratified population , 2010, Journal of The Royal Society Interface.

[29]  Marc Lipsitch,et al.  Use of Cumulative Incidence of Novel Influenza A/H1N1 in Foreign Travelers to Estimate Lower Bounds on Cumulative Incidence in Mexico , 2009, PloS one.

[30]  A. Flahault,et al.  Estimating the impact of school closure on influenza transmission from Sentinel data , 2008, Nature.

[31]  Nadav Davidovitch,et al.  Cost-Benefit of Stockpiling Drugs for Influenza Pandemic , 2005, Emerging infectious diseases.

[32]  Sandra Mounier-Jack,et al.  Pandemic influenza: are Europe's institutions prepared? , 2006, European journal of public health.

[33]  R. Anderson,et al.  Potential public health impact of imperfect HIV type 1 vaccines. , 2005, The Journal of infectious diseases.

[34]  M. Postma,et al.  Mitigation of pandemic influenza: review of cost–effectiveness studies , 2009, Expert review of pharmacoeconomics & outcomes research.

[35]  N. Ferguson,et al.  Closure of schools during an influenza pandemic , 2009, The Lancet Infectious Diseases.

[36]  C. Macken,et al.  Mitigation strategies for pandemic influenza in the United States. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Christophe Fraser,et al.  The Effectiveness of Contact Tracing in Emerging Epidemics , 2006, PloS one.

[38]  Laura M. Glass,et al.  Targeted Social Distancing Designs for Pandemic Influenza , 2006, Emerging infectious diseases.

[39]  P. Horby,et al.  Nonpharmaceutical Interventions for Pandemic Influenza, National and Community Measures , 2006, Emerging infectious diseases.

[40]  M. Safan,et al.  Pros and cons of estimating the reproduction number from early epidemic growth rate of influenza A (H1N1) 2009 , 2010, Theoretical Biology and Medical Modelling.

[41]  C. Fraser,et al.  Reducing the impact of the next influenza pandemic using household-based public health interventions. , 2006, Hong Kong medical journal = Xianggang yi xue za zhi.

[42]  Nilimesh Halder,et al.  Analysis of the effectiveness of interventions used during the 2009 A/H1N1 influenza pandemic , 2010, BMC public health.

[43]  J. Medlock,et al.  Optimizing Influenza Vaccine Distribution , 2009, Science.

[44]  R. May,et al.  Infectious Diseases of Humans: Dynamics and Control , 1991, Annals of Internal Medicine.

[45]  Alessandro Vespignani,et al.  Modeling the Worldwide Spread of Pandemic Influenza: Baseline Case and Containment Interventions , 2007, PLoS medicine.

[46]  N. Ferguson,et al.  Will travel restrictions control the international spread of pandemic influenza? , 2006, Nature Medicine.

[47]  Marc Lipsitch,et al.  Hedging against Antiviral Resistance during the Next Influenza Pandemic Using Small Stockpiles of an Alternative Chemotherapy , 2009, PLoS medicine.

[48]  C. Fraser,et al.  Epidemiology, transmission dynamics and control of SARS: the 2002-2003 epidemic. , 2004, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[49]  W. Edmunds,et al.  Delaying the International Spread of Pandemic Influenza , 2006, PLoS medicine.

[50]  D. Cummings,et al.  Strategies for containing an emerging influenza pandemic in Southeast Asia , 2005, Nature.

[51]  Sandra Mounier-Jack,et al.  Progress and shortcomings in European national strategic plans for pandemic influenza. , 2007, Bulletin of the World Health Organization.